Dashboard
Manage Tickers

AMRX Amneal Pharmaceuticals, Inc.

Nasdaq amneal.com


$ 11.94 $ -0.10 (-0.83 %)    

Wednesday, 12-Nov-2025 12:06:02 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 619.54 $ -5.21 (-0.83 %)
DIA $ 483.15 $ 2.55 (0.53 %)
SPY $ 682.43 $ -2.36 (-0.34 %)
TLT $ 90.24 $ 0.29 (0.32 %)
GLD $ 386.16 $ 6.04 (1.59 %)
$ 11.95
$ 11.97
$ 11.92 x 6
$ 11.96 x 224
$ 11.85 - $ 12.06
$ 6.69 - $ 12.09
3,211,406
na
3.76B
$ 1.07
$ 636.72
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 02-28-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-09-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 03-14-2024 12-31-2023 10-K
9 11-08-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-03-2023 12-31-2022 10-K
13 11-07-2022 09-30-2022 10-Q
14 08-08-2022 06-30-2022 10-Q
15 05-06-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-08-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-06-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-02-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-05-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 03-01-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 03-09-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

piper-sandler-reiterates-overweight-on-amneal-pharmaceuticals-raises-price-target-to-13
Piper Sandler Reiterates Overweight on Amn...
10/31/2025 15:38:03

Piper Sandler analyst David Amsellem reiterates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price ...

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

amneal-pharmaceuticals-raises-fy2025-adj-eps-guidance-from-070-075-to-075-080-vs-077-est-affirms-fy2025-sales-guidance-of-3000b-3100b-vs-3011b-est
Amneal Pharmaceuticals Raises FY2025 Adj E...
10/30/2025 10:02:04

Amneal Pharmaceuticals (NASDAQ:AMRX) raises FY2025 Adj EPS guidance from $0.70-$0.75 to $0.75-$0.80 vs $0.77 analyst estimate. ...

amneal-pharmaceuticals-q3-adj-eps-017-beats-014-estimate-sales-784513m-beat-772310m-estimate
Amneal Pharmaceuticals Q3 Adj. EPS $0.17 B...
10/30/2025 10:00:56

Amneal Pharmaceuticals (NASDAQ:AMRX) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate o...

amneal-pharmaceuticals-granted-fda-tentative-approval-for-beclomethasone-dipropionate-hfa-inhalation-aerosol
Amneal Pharmaceuticals Granted FDA Tentati...
10/29/2025 20:07:59

Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced that the U.S. Food and Drug Administra...

amneal-launches-brekiya-dhe-autoinjector-for-adults-with-migraine
Amneal Launches Brekiya DHE Autoinjector F...
10/27/2025 12:04:08

teva-viatris-on-investor-watch-as-white-house-spares-generic-drugs-from-tariffs
Teva, Viatris On Investor Watch As White H...
10/09/2025 13:31:09

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply...

amneal-pharma-submits-bla-to-fda-for-proposed-biosimilar-to-xolair-developed-by-kashiv-biosciences
Amneal Pharma Submits BLA To FDA For Propo...
09/26/2025 12:05:38

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) ("Amneal" or the "Company") today announced the submission of a Bio...

fda-approves-amneal-pharmaceuticalss-abbreviated-new-drug-application-for-bimatoprost-ophthalmic-solution-001
FDA Approves Amneal Pharmaceuticals's Abbr...
09/23/2025 12:04:53

jp-morgan-maintains-overweight-on-amneal-pharmaceuticals-raises-price-target-to-14
JP Morgan Maintains Overweight on Amneal P...
09/16/2025 11:38:50

JP Morgan analyst Chris Schott maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target ...

amneal-announces-fda-approval-of-sodium-oxybate-oral-solution
Amneal Announces FDA Approval Of Sodium Ox...
09/11/2025 12:07:39

amneal-pharmaceuticals-announce-sfda-approval-for-risperidone-extended-release-injectable-suspension
Amneal Pharmaceuticals Announce sFDA Appro...
09/04/2025 20:01:41

amneal-pharmaceuticals-raises-fy2025-adj-eps-guidance-from-065-070-to-070-075-vs-070-est-affirms-fy2025-sales-guidance-of-3000b-3100b-vs-3012b-est
Amneal Pharmaceuticals Raises FY2025 Adj E...
08/05/2025 10:02:35

Raising Full Year 2025 Financial GuidanceThe Company is raising its previously provided full year 2025 guidance.Updated Guidanc...

amneal-pharmaceuticals-q2-2025-adj-eps-025-beats-017-estimate-sales-725000m-miss-753343m-estimate
Amneal Pharmaceuticals Q2 2025 Adj. EPS $0...
08/05/2025 10:01:06

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

a-peek-at-amneal-pharmaceuticalss-future-earnings
A Peek at Amneal Pharmaceuticals's Future ...
08/04/2025 16:03:58

amneal-pharmas-subsidiary-pursues-18b-term-loan-facility-launches-750m-senior-secured-notes-offering
Amneal Pharma's Subsidiary Pursues $1.8B T...
07/21/2025 11:45:16

Amneal Pharmaceuticals, Inc. ("Amneal") (NASDAQ:AMRX) announced that its subsidiary, Amneal Pharmaceuticals LLC (the &#...

amneal-pharma-preliminary-q2-net-revenue-720m---730m-up-3-yoy-adj-ebitda-180m---185m-up-13-yoy
Amneal Pharma Preliminary Q2 Net Revenue $...
07/21/2025 11:43:25

– Results Reflect Continued Financial Strength and Deleveraging –BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Ph...

Core News & Articles
NY State Attorney General Letetia James Po...
07/10/2025 17:49:09

https://x.com/NewYorkStateAG/status/1943364781936607687  

amneal-pharmaceuticals-highlights-confirmatory-clinical-study-of-adl-018
Amneal Pharmaceuticals Highlights Confirma...
06/25/2025 12:08:09

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION